Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities

Area of Science:

• Neuroscience
• Metabolic Disorders
• Pharmacology

Background:

• Depressive disorder is a prevalent mental illness with a complex relationship to metabolic disorders.
• Conventional antidepressants have limited efficacy, necessitating novel therapeutic targets.
• Shared molecular mechanisms link metabolic dysfunction and depression, suggesting a common pathophysiology.

Purpose of the Study:

• To review metabolic modulators as potential antidepressant strategies.
• To focus on molecular mechanisms, preclinical, and clinical findings.
• To explore the integration of these agents into future depression therapies.

Main Methods:

• Review of preclinical and clinical studies on metabolic modulators.
• Analysis of molecular pathways involved in depression and metabolic disorders.
• Evaluation of agents targeting Glucagon-Like Peptide-1 receptors (GLP-1 RAs), Sodium-Glucose Cotransporter-2 (SGLT2), Peroxisome Proliferator-Activated Receptor alpha (PPARα), and the renin-angiotensin-aldosterone system (RAAS).

Main Results:

• GLP-1 RAs and SGLT2 inhibitors demonstrate neurotrophic, anti-inflammatory, antioxidant, and mitochondrial benefits, showing antidepressant-like effects in preclinical studies.
• PPARα agonists may improve neuronal plasticity and mood regulation by modulating lipid and glucose metabolism.
• ARBs and ARNIs exert central anti-inflammatory and neuroprotective effects via RAAS modulation, relevant to affective disorders.

Conclusions:

• Metabolic modulators offer potential as novel antidepressant strategies by addressing shared pathophysiological mechanisms with metabolic disorders.
• Agents like GLP-1 RAs, SGLT2 inhibitors, PPARα agonists, ARBs, and ARNIs show promise.
• Long-term, head-to-head trials are essential to establish efficacy, safety, and therapeutic positioning for depression treatment.